132 related articles for article (PubMed ID: 34245852)
1. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.
Wu F; Yao H; Li W; Zhang N; Fan Y; Chan ASC; Li X; An B
Bioorg Med Chem Lett; 2021 Sep; 48():128253. PubMed ID: 34245852
[TBL] [Abstract][Full Text] [Related]
2. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
[TBL] [Abstract][Full Text] [Related]
3. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.
Li T; Li C; Yang J; Guo M; Cao Z; Wang X; Jiang N; Zhai X
Bioorg Med Chem; 2021 Oct; 47():116396. PubMed ID: 34534734
[TBL] [Abstract][Full Text] [Related]
5. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation N
Xing L; Jing T; Zhang J; Guo M; Miao X; Jiang F; Zhai X
Bioorg Chem; 2018 Dec; 81():689-699. PubMed ID: 30268049
[TBL] [Abstract][Full Text] [Related]
8. Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.
Li Z; Guo M; Cao M; Zhao T; Li M; Zhai X
Bioorg Med Chem; 2021 May; 37():116108. PubMed ID: 33756437
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
[TBL] [Abstract][Full Text] [Related]
11. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
15. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.
Achary R; Mathi GR; Lee DH; Yun CS; Lee CO; Kim HR; Park CH; Kim P; Hwang JY
Bioorg Med Chem Lett; 2017 May; 27(10):2185-2191. PubMed ID: 28385505
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
17. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
18. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
19. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells.
Wang L; Xu X; Liu T; Wang J; Shen J; Guo M; Wu Y; Zhai X; Zuo D
J Pharm Pharmacol; 2020 Oct; 72(10):1370-1382. PubMed ID: 32596809
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
